What is Zacks Research’s Estimate for RDY FY2026 Earnings?

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Stock analysts at Zacks Research cut their FY2026 earnings estimates for shares of Dr. Reddy’s Laboratories in a report released on Wednesday, February 11th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.64 per share for the year, down from their previous forecast of $0.69. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2026 earnings at $0.09 EPS, Q2 2027 earnings at $0.17 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.09 EPS, FY2027 earnings at $0.56 EPS, Q3 2028 earnings at $0.16 EPS and FY2028 earnings at $0.63 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Wednesday, January 21st. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $969.81 million during the quarter, compared to analysts’ expectations of $963.84 million. Dr. Reddy’s Laboratories had a return on equity of 15.89% and a net margin of 16.41%.

Separately, Weiss Ratings upgraded Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, January 30th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Dr. Reddy’s Laboratories has an average rating of “Moderate Buy” and a consensus price target of $16.90.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock opened at $14.29 on Thursday. The company has a current ratio of 1.88, a quick ratio of 1.38 and a debt-to-equity ratio of 0.03. The company has a market cap of $11.93 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 12.91 and a beta of 0.35. The company has a 50 day moving average of $13.78 and a 200-day moving average of $14.02. Dr. Reddy’s Laboratories has a 1-year low of $12.26 and a 1-year high of $16.17.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Large investors have recently bought and sold shares of the stock. Brooklyn Investment Group increased its position in shares of Dr. Reddy’s Laboratories by 62.6% during the fourth quarter. Brooklyn Investment Group now owns 60,728 shares of the company’s stock worth $857,000 after acquiring an additional 23,381 shares in the last quarter. Orion Porfolio Solutions LLC boosted its holdings in Dr. Reddy’s Laboratories by 35.6% during the 4th quarter. Orion Porfolio Solutions LLC now owns 109,028 shares of the company’s stock worth $1,531,000 after acquiring an additional 28,597 shares during the last quarter. Commonwealth Equity Services LLC bought a new stake in shares of Dr. Reddy’s Laboratories in the 4th quarter worth $211,000. Bank of Montreal Can raised its holdings in shares of Dr. Reddy’s Laboratories by 249.5% in the fourth quarter. Bank of Montreal Can now owns 40,260 shares of the company’s stock valued at $565,000 after purchasing an additional 28,742 shares during the last quarter. Finally, Alps Advisors Inc. purchased a new stake in shares of Dr. Reddy’s Laboratories in the fourth quarter valued at about $885,000. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.